SCHEDULE: Balyasny Asset Management Increases Stake in Lexeo Therapeutics

Balyasny Asset Management L.P. and affiliated entities have reported a beneficial ownership of 9.69% in Lexeo Therapeutics, Inc. common stock as of March 31, 2026.

Summary

• Balyasny Asset Management L.P. (BAM), along with its related entities BAM GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC, and Dmitry Balyasny, collectively known as the Reporting Persons, have disclosed their beneficial ownership of Lexeo Therapeutics, Inc. common stock.
• As of March 31, 2026, the Reporting Persons beneficially own 7,176,144 shares, representing 9.69% of the outstanding common stock.
• This ownership includes 1,589,585 directly held shares and 5,586,529 shares issuable upon the exercise of warrants.
• The exercise of these warrants is subject to a Beneficial Ownership Limitation, preventing exercise if it would result in beneficial ownership exceeding 9.99% of the outstanding shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting existing ownership stakes and warrant limitations, without providing new financial performance data or strategic outlook.

Positives

• Significant beneficial ownership stake of 9.69% in Lexeo Therapeutics, Inc. common stock.
• Control over a substantial number of shares (7,176,144) including those issuable from warrants.

Negatives

• The exercise of warrants is capped by a Beneficial Ownership Limitation, restricting the ability to acquire more shares if it exceeds 9.99% ownership.

Risks

• The Beneficial Ownership Limitation on warrants could restrict future share acquisition and potential influence.
• Changes in Lexeo Therapeutics, Inc.'s stock performance could impact the value of the Reporting Persons' investment.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from management regarding future performance. The primary focus is on current beneficial ownership and the limitations associated with warrant exercise.

Industry Context

StockSavvy.ai notes that this Schedule 13G filing indicates a significant institutional investor's stake in Lexeo Therapeutics, Inc. Such filings are common for asset managers accumulating positions in publicly traded companies, often signaling confidence or strategic interest in the company's prospects within the biotechnology or pharmaceutical sector.

Stakeholder Impact

• Shareholders: The increased stake by a significant asset manager may be viewed positively, potentially indicating confidence in the company's future, but the ownership cap on warrants limits immediate further acquisition.
• Management: The filing provides transparency on significant ownership, which is a standard disclosure requirement.
• Creditors: No direct impact is indicated.

Next Steps

• The Reporting Persons will continue to hold their beneficial ownership in Lexeo Therapeutics, Inc.
• Future actions may be influenced by the Beneficial Ownership Limitation on warrant exercise.

Key Dates

Keywords

Lexeo Therapeutics, Balyasny Asset Management, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, SEC Filing, Investment Management